David van Veenhuyzen, M.B., Ch.B., M.Pharm.Med.
QED Therapeutics, a BridgeBio company
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David van Veenhuyzen, M.B., Ch.B., M.Pharm.Med. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:14 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04197986 · Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsQED Therapeutics, a BridgeBio company · terminated · Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.